Dane Leone
Stock Analyst at Raymond James
(1.18)
# 3,771
Out of 5,090 analysts
69
Total ratings
33.96%
Success rate
-6.9%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $7.68 | +147.40% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.73 | +447.80% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $13.16 | +241.95% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $79.64 | -62.33% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $718.36 | +32.25% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.80 | +622.22% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $73.64 | -37.53% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $31.59 | +118.42% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $5.53 | +44.67% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $12.58 | +11.29% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $17.30 | +235.26% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $19.64 | +256.42% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.43 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $65.67 | -4.07% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $52.15 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.35 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $81.77 | -20.51% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $329.89 | -22.70% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.28 | +647.66% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $201.93 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $7.68
Upside: +147.40%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.73
Upside: +447.80%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $13.16
Upside: +241.95%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $79.64
Upside: -62.33%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $718.36
Upside: +32.25%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.80
Upside: +622.22%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $73.64
Upside: -37.53%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $31.59
Upside: +118.42%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $5.53
Upside: +44.67%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $12.58
Upside: +11.29%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $17.30
Upside: +235.26%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $19.64
Upside: +256.42%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.43
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $65.67
Upside: -4.07%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $52.15
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.35
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $81.77
Upside: -20.51%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $329.89
Upside: -22.70%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.28
Upside: +647.66%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $201.93
Upside: -